$0.33
1.43% today
Nasdaq, Jul 15, 06:20 pm CET
ISIN
US72941H4002
Symbol
PSTV
Sector
Industry

Plus Therapeutics Inc Stock price

$0.34
+0.03 8.87% 1M
-0.83 71.26% 6M
-0.81 70.76% YTD
-1.43 81.00% 1Y
-7.48 95.70% 3Y
-32.96 98.99% 5Y
-58,522.16 100.00% 10Y
-371,249.66 100.00% 20Y
Nasdaq, Closing price Mon, Jul 14 2025
-0.02 6.51%
ISIN
US72941H4002
Symbol
PSTV
Sector
Industry

Key metrics

Basic
Market capitalization
$17.2m
Enterprise Value
$7.3m
Net debt
positive
Cash
$9.9m
Shares outstanding
17.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.3 | 2.6
EV/Sales
1.4 | 1.1
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-134.9%
Return on Equity
145.0%
ROCE
-995.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$5.2m | $6.6m
EBITDA
$-14.2m | $-14.1m
EBIT
$-14.9m | $-18.7m
Net Income
$-27.1m | $-13.7m
Free Cash Flow
$-12.9m
Growth (TTM | estimate)
Revenue
-14.3% | 14.2%
EBITDA
-26.1% | -0.8%
EBIT
-25.5% | -27.4%
Net Income
-130.4% | -5.6%
Free Cash Flow
-10.3%
Margin (TTM | estimate)
Gross
-
EBITDA
-273.1% | -211.8%
EBIT
-286.8%
Net
-520.9% | -206.2%
Free Cash Flow
-247.2%
More
EPS
$-1.9
FCF per Share
$-0.8
Short interest
3.6%
Employees
21
Rev per Employee
$280.0k
Show more

Is Plus Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Plus Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Plus Therapeutics Inc forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Plus Therapeutics Inc forecast:

Buy
80%
Hold
20%

Financial data from Plus Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
5.21 5.21
14% 14%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 11 11
24% 24%
203%
- Research and Development Expense 9.57 9.57
1% 1%
184%
-14 -14
26% 26%
-273%
- Depreciation and Amortization 0.71 0.71
15% 15%
14%
EBIT (Operating Income) EBIT -15 -15
25% 25%
-287%
Net Profit -27 -27
130% 130%
-521%

In millions USD.

Don't miss a Thing! We will send you all news about Plus Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Plus Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about 5 hours ago
Presentation by trial principal investigator at the 2025 SNO/ASCO CNS Metastases Conference Plus will also host an educational symposium with leading experts titled, “Reimagining Your Approach to Leptomeningeal Metastases” HOUSTON, July 15, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeuti...
Neutral
GlobeNewsWire
5 days ago
The Joint Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) focus on the rapidly evolving area of central nervous system metastases
Neutral
GlobeNewsWire
7 days ago
Substantial clinical need expected to facilitate rapid overall trial enrollment Substantial clinical need expected to facilitate rapid overall trial enrollment
More Plus Therapeutics Inc News

Company Profile

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. Its products include Rhenium NanoLiposome (RNL) and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Head office United States
CEO Marc Hedrick
Employees 21
Founded 1996
Website www.plustherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today